Publication:
Conventional tools for predicting satisfactory response to neoadjuvant chemotherapy in HR+/HER2- breast cancer patients

Simple item page
dc.contributor.authorGÜLLÜOĞLU, MAHMUT BAHADIR
dc.contributor.authorEREN, ÖZGÜR CAN
dc.contributor.authorKAYA, HANDAN
dc.contributor.authorUĞURLU, MUSTAFA ÜMİT
dc.contributor.authorsOprea A. L., GÜLLÜOĞLU M. B., Aytin Y. E., EREN Ö. C., Aral C., Szekely T. B., TAŞTEKİN E., KAYA H., BADEMLER S., Karanllk H., et al.
dc.date.accessioned2023-11-27T08:48:00Z
dc.date.available2023-11-27T08:48:00Z
dc.date.issued2023-10-01
dc.description.abstractAim: The aim of the study was to assess the role of Magee Equation 3 (MagEq3), IHC4 score, and HER2-low status in predicting \"satisfactory response (SR)\"to neoadjuvant chemotherapy (NAC) in HR+/HER2- breast cancer (BC) patients. Methods: In a retrospective study, female patients of any age with T1-4, N0-2, M0 HR+/HER2- BC who received NAC and underwent adequate locoregional surgical treatment were included. Patients were grouped according to 2 outcomes: (a) overall response to NAC in breast and axilla by using residual cancer burden (RCB) criteria and (b) axillary downstaging after NAC by using N staging. 2 cohorts for overall response were overall SR (RCB 0-1) and no SR (RCB 2-3). On the other hand, for axillary downstaging, 2 cohorts constituted from axillary SR (ypN0 and ypN0i+) and no SR (ypNmic-N3). MagEq3 and IHC4 scores were calculated from their pathological tumor slides in each patient. HER2 status was categorized as either \"no\"or \"low.\"In addition, patient age, family history, tumor histology, stage at admission, and Ki-67 status were compared between cohorts according to predefined outcomes. Results: In a total of 230 BC patients, 228 patients were included to compare according to their RCB levels. The mean age of patients with overall SR was significantly lower than those without. Patients with high Ki-67 expression, high (>30) MagEq3 score, high ICH4 quartile, and HER2-low status had significantly more overall SR. On the other hand, only patients with high Ki-67 expression had significantly more axillary SR. MagEq3 score levels, ICH4 quartiles, and HER2 status were similar between patients with axillary SR and not. Conclusion: MagEq3 and IHC4 tools seemed to be useful to predict those HR+/HER2- BC patients who are most likely to get benefit from NAC. But, only high Ki-67 expression level significantly predicted satisfactory axillary downstaging in HR+/HER2- BC patients.
dc.identifier.citationOprea A. L., GÜLLÜOĞLU M. B., Aytin Y. E., EREN Ö. C., Aral C., Szekely T. B., TAŞTEKİN E., KAYA H., BADEMLER S., Karanllk H., et al., "Conventional Tools for Predicting Satisfactory Response to Neoadjuvant Chemotherapy in HR+/HER2- Breast Cancer Patients", Breast Care, cilt.18, sa.5, ss.344-353, 2023
dc.identifier.doi10.1159/000531117
dc.identifier.endpage353
dc.identifier.issn1661-3791
dc.identifier.issue5
dc.identifier.startpage344
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85176335134&origin=inward
dc.identifier.urihttps://hdl.handle.net/11424/295149
dc.identifier.volume18
dc.language.isoeng
dc.relation.ispartofBreast Care
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectCerrahi Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectMedicine
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectOncology
dc.subjectSurgery Medicine Sciences
dc.subjectHealth Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectCERRAHİ
dc.subjectONKOLOJİ
dc.subjectClinical Medicine (MED)
dc.subjectCLINICAL MEDICINE
dc.subjectSURGERY
dc.subjectONCOLOGY
dc.subjectCerrahi
dc.subjectSurgery
dc.titleConventional tools for predicting satisfactory response to neoadjuvant chemotherapy in HR+/HER2- breast cancer patients
dc.typearticle
dspace.entity.typePublication
local.avesis.id70e2d109-19b9-4d09-b0a0-0edce01d1355
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublication6d478db0-15a8-4b2b-878f-dc3d1b256022
relation.isAuthorOfPublication706822bb-ab1e-4e67-926d-9cec42a2b6e7
relation.isAuthorOfPublication0bf301ff-2544-4a5e-b38b-b43084d6c255
relation.isAuthorOfPublication76044dc9-a441-4103-b46d-5d995fec91d4
relation.isAuthorOfPublication.latestForDiscovery6d478db0-15a8-4b2b-878f-dc3d1b256022

Files

Collections

Research Outputs